share_log

Lakeside Partners With Huiyu Pharmaceutical to Revolutionize Oncology Drug Distribution

Lakeside Partners With Huiyu Pharmaceutical to Revolutionize Oncology Drug Distribution

湖畔與慧宇藥品合作,革新腫瘤藥品經銷。
PR Newswire ·  01/07 21:30

ITASCA, Ill., Jan. 7, 2025 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market today announced that Hupan Pharmaceutical has entered into a strategic distribution agreement with Sichuan Huiyu Pharmaceutical Co., Ltd. ("Huiyu Pharmaceutical").

伊塔斯卡,伊利諾伊州,2025年1月7日 /PRNewswire/ -- Lakeside Holding Limited(「Lakeside」或「公司」)(納斯達克:LSH),一家總部位於美國,專注於亞太市場的跨境供應鏈解決方案提供商,今天宣佈,Hupan Pharmaceutical與四川匯宇藥業有限公司(「匯宇藥業」)達成了戰略分銷協議。

Huiyu Pharmaceutical is a leading innovator in oncology and immune-related therapies, listed on the Shanghai Stock Exchange (688553.SS). Huiyu Pharmaceutical is renowned for its robust R&D capabilities, cutting-edge manufacturing process, and a strong commitment to address critical healthcare needs worldwide.

匯宇藥業是一家在腫瘤學和免疫相關療法方面的領先創新者,上市於上海證券交易所(688553.SS)。匯宇藥業因其強大的研發能力、尖端的生產工藝和對全球關鍵醫療需求的強烈承諾而聞名。

Under the agreement, Hupan Pharmaceutical will distribute Huiyu Pharmaceutical's highly regarded oncology and immunotherapy drugs to hospitals and healthcare institutions to domestic and global markets. Huiyu Pharmaceutical's flagship product, Pemetrexed Disodium for Injection, has received regulatory approvals in major markets, including China, the UK, Germany, and Finland, and is widely recognized for its efficacy in treating non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

根據協議,Hupan Pharmaceutical將把匯宇藥業備受推崇的腫瘤學和免疫治療藥物分銷到國內和全球市場的醫院和醫療機構。匯宇藥業的旗艦產品注射用培美曲塞二鈉已在中國、英國、德國和芬蘭等主要市場獲得監管批准,並因其在治療非小細胞肺癌(NSCLC)和惡性胸膜間皮瘤方面的療效而廣泛認可。

Lan Su, COO of Lakeside Holding Limited, commented, "Our strategic partnership with Huiyu Pharmaceutical allows us to help expand the reach of their innovative oncology solutions and deliver life-saving treatments to broader markets. We are proud to use our healthcare distribution capabilities to reach patients domestically and abroad."

Lakeside Holding Limited的首席運營官Lan Su評論道:「我們與匯宇藥業的戰略合作伙伴關係使我們能夠幫助擴展他們創新腫瘤治療方案的覆蓋範圍,並將救命治療送到更廣泛的市場。我們自豪地利用我們的醫療分銷能力,服務國內外患者。」

Zhao Ding, President at Huiyu Pharmaceutical, commented, "We look forward to partnering with Hupan Pharmaceutical to provide reliable and efficient distribution channels for our therapies, so they can reach patients when needed and improve patient outcomes."

匯宇藥業總裁趙丁評論道:「我們期待與Hupan Pharmaceutical合作,爲我們的療法提供可靠和高效的分銷渠道,以便在需要時可以迅速到達患者並改善患者的治療效果。」

About Lakeside Holding Limited

關於湖邊控股有限公司

Lakeside Holding Limited is a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market. Through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd.—Lakeside delivers tailored logistics solutions spanning general and specialized sectors.

湖邊控股有限公司是一家總部位於美國的跨境供應鏈解決方案提供商,獨特聚焦於亞太市場。通過兩家專業子公司——美國熊物流和胡盤藥品(湖北)有限公司——湖邊提供涵蓋一般和專業行業的定製物流解決方案。

American Bear Logistics, with strategic hubs in Chicago, Dallas, Los Angeles, and New York, offers customized cross-border ocean and airfreight solutions, connecting Asia-based logistics service companies and e-commerce platforms with the U.S. market.

美國熊物流在芝加哥、達拉斯、洛杉磯和紐約設有戰略中心,提供定製的跨境海運和空運解決方案,連接亞基的物流服務公司和電子商務平台與美國市場。

Lakeside recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd., expanding its service scope and enhancing its pharmaceutical logistics and distribution capabilities within China. This strategic move underscores Lakeside's commitment to advancing integrated cross-border logistics solutions.

Lakeside最近收購了湖北匯潘藥業有限公司,擴展了其服務範圍,增強了在中國的藥品物流和分銷能力。這一策略舉措突顯了Lakeside致力於推進綜合跨境物流解決方案的承諾。

For more information, please visit .

欲了解更多信息,請訪問。

Safe Harbor Statement

安全港聲明

This press release contains forward-looking statements that reflect our current expectations and views of future events. Known and unknown risks, uncertainties and other factors, including those listed under "Risk Factors," may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements.

本新聞稿包含前瞻性陳述,反映了我們當前的期望和對未來事件的看法。已知和未知的風險、不確定性及其他因素,包括在「風險因素」下列出的因素,可能導致我們的實際結果、業績或成就與前瞻性陳述所表達或暗示的內容有實質性不同。您可以通過諸如「可能」、「將」、「預期」、「anticipate」、「目標」、「估計」、「打算」、「計劃」、「相信」、「可能會」、「潛在」、「繼續」或其他類似表達來識別這些前瞻性陳述。我們將這些前瞻性陳述在很大程度上基於我們關於可能影響我們財務狀況、運營結果、業務策略和財務需求的未來事件的當前期望和預測。這些前瞻性陳述涉及多種風險和不確定性。除法律要求外,我們不承擔更新或修改任何前瞻性陳述的公開義務,無論是由於新信息、未來事件還是其他原因,均在聲明發佈日期後,亦不反映未預見事件的發生。我們通過這些警示性聲明來限定我們所有的前瞻性陳述。

Investor Relations Contact:

投資者關係聯繫:

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: [email protected]

Strategic Investor Relations, LLC的IRC Matthew Abenante
總裁
戰略投資者關係有限責任公司
電話:347-947-2093
電子郵件: [email protected]

SOURCE Lakeside Holding Limited

來源 湖濱控股有限公司

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?

440k+
440k+

Newsrooms &
新聞編輯室和

Influencers
意見領袖
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
已選擇加入
GET STARTED
開始

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論